User login
Case
An 86-year-old woman, who recently had been seen in the same facility after a ground level fall, presented to the ED with to a 2- to 3-day history of vague abdominal pain, increasing weakness, nausea, and dry heaves.
Upon examination, the patient was unable to stand due to generalized weakness She arrived at the ED via emergency medical services. Her vital signs at presentation were significant for a systolic blood pressure (BP) of 90 mm Hg with a wide complex tachycardia concerning for ventricular tachycardia. The patient’s other vital signers were: heart rate, 136 beats/min; respiratory rate 20 breaths/min; and pulse oximetry was 94% on 4 liters/min of oxygen via nasal cannula.
The patient’s medical history was significant for atrial fibrillation and an indwelling pacemaker, for which she was chronically on flecai
The initial electrocardiogram (ECG) revealed a wide complex rhythm with pacemaker spikes (Figure 1). Based on these findings, electrodes were placed on the patient in the event she required cardioversion. The patient was started on an amiodarone intravenous (IV) drip for presumptive ventricular tachycardia.
During the patient’s evaluation in the ED, she experienced transient drops in BP, which were responsive to an IV fluid bolus of normal saline, and the amiodarone drip was discontinued. The patient’s ECG findings were compared to previous ECG studies, as was her current medication list and prior health issues. After ruling-out other causes, flecainide toxicity was considered high in the differential, and she was given 1 ampule of bicarbonate IV, after which a second ECG showed heart rhythm converted from a wide-complex tachycardia to a paced rhythm, markedly improved from the initial ECG (Figure 2). Similarly, there was a marked improvement in BP.
An interrogation of the patient’s pacemaker revealed an atrial flutter with a rate below detection for mode switch, with one-to-one tracking/pacing. The pacemaker was reprogrammed to divide the DDIR mode with detection rate at 120 mm Hg with mode switch activated. This was felt to be consistent with flecainide toxicity precipitating the cardiac conduction issues.
Laboratory studies showed an elevated flecainide level at 1.39 mcg/mL (upper limits of normal of 1 mcg/mL). Other studies showed worsening congestive heart failure, with a brain natriuretic peptide of 8,057 pg/mL and mild dehydration, with serum creatinine increased from her baseline of 0.9 to 1.38 mg/dL.
The patient’s abdominal pain was further evaluated and she was found to have acute cholecystitis. She was admitted to the intensive care unit with cardiology and general surgery consulting.
Discussion
Flecainide acetate was approved by the Food and Drug Administration in 1984.1It is a Vaughan-Williams class IC antiarrhythmic with a sodium channel blocker action used to treat supra ventricular arrhythmias. The CAST trial in 1989 investigated the efficacy of this class of antiarrhythmics, which resulted in a revision of its role.2 Based on this study, flecainide is not recommended for patients with structural heart disease or coronary artery disease.2,3 However, it is recommended as a first-line therapy for pharmacologic cardioversion and maintenance of normal sinus rhythm in patients with atrial fibrillation and supraventricular tachycardia4,5 without the above caveats.
Class IC agents produce a selective block at the sodium (Na+) channels, resulting in the slowing of cardiac conduction.6,7 This high affinity for Na+ channels combined with slow unbinding kinetics during diastole explain the slowing of recovery time and prolongation of the refractory period.6,8,9 These electrophysiologic properties all can increase the PR, QRS, and QT interval duration. The QT interval is not significantly affected, as most of the QT prolongation is due to the QRS widening.6,10,11 Widening of the QRS by greater than 25% as compared to the baseline value is used as the threshold to decrease dosing or discontinue the use of flecainide.3The toxic effects of flecainide on cardiac conduction can produce prolonged QRS duration of up to 50%, and PR interval up to 30%, especially in rapid heart rates. Signs of intoxication are difficult to discern owing to its nonspecific presentation. A well-documented, but under-recognized, presentation of flecainide toxicity is the transformation of atrial fibrillation to atrial flutter.5,7,9,11-13 The reported rate of this pro arrhythmic effect can be as high as 3.5% to 5%.14,15Flecainide toxicity can occur secondary to chronic ingestion and may be precipitated in mild renal failure. The majority of flecainide is renally excreted and the half-life is 20 hours. Maximum therapeutic effect is seen between levels of 0.2 to 1 mcg/mL with levels greater than 0.7 to 1 mcg/mL associated with adverse effects.9 Systemic effects include dizziness and visual disturbances. A high degree of suspicion for flecainide toxicity is required when the patient’s initial presentation is nonspecific. In this circumstance, real-time bedside interrogation of the pacemaker is invaluable. Early diagnosis and treatment minimizes the risk for adverse sequelae, including death. Treatment includes increasing the excretion of flecainide, symptomatic support (including pacemaker placement, intravenous fat emulsion, or extracorporeal circulatory support) and administration of sodium bicarbonate, to transiently reverse the effect of the sodium channel blockade, in severe cases.15-17
1. Hudak JM, Banitt EH, Schmid JR. Discovery and development of flecainide. Am J Cardiol. 1984;53(5):17B-20B.
2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med. 1989;321(6):406-412. doi:10.1056/NEJM198908103210629.
3. Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol. 2015;7(2):76-85. doi:10.4330/wjc.v7.i2.76.
4. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747. doi:10.1093/eurheartj/ehs253.
5. Courand PY, Sibellas F, Ranc S, Mullier A, Kirkorian G, Bonnefoy E. Arrhythmogenic effect of flecainide toxicity. Cardiol J. 2013;20:203-205. doi:10.5603/CJ.2013.0035.
6. Holmes B, Heel RC. Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29(1):1-33.
7. Taylor R, Gandhi MM, Lloyd G. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. Br Med J. 2010;340:b4684.
8. Roden DM, Woosley RL. Drug therapy. Flecainide. N Engl J Med. 1986;315(1):36-41.
9. Levis JT. ECG diagnosis: flecainide toxicity. Perm J. 2012;16(4):53.
10. Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RA, Camm AJ. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J. 1982;48(2):140-148.
11. Rognoni A, Bertolazzi M, Peron M, et al. Electrocardiographic changes in a rare case of flecainide poisoning: a case report. Cases J. 2009;2:9137. doi:10.1186/1757-1626-2-9137.
12. Nabar A, Rodriguez LM, Timmermans C, Smeets JL, Wellens HJ. Radiofrequency ablation of “class IC atrial flutter” in patients with resistant atrial fibrillation. Am J Cardiol. 1999;83(5):785-787, A10.
13. Kola S, Mahata I, Kocheril AG. A case of flecainide toxicity. EP Lab Digest. 2015;15(5).
14. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992;117(2):141-150.
15. Lloyd T, Zimmerman J, Griffin GD. Irreversible third-degree heart block and pacemaker implant in a case of flecainide toxicity. Am J Emerg Med. 2013;31(9):1418.e1-e2. doi:10.1016/j.ajem.2013.04.025.
16. Corkeron MA, van Heerden PV, Newman SM, Dusci L. Extracorporeal circulatory support in near-fatal flecainide overdose. Anaesth Intensive Care. 1999;27(4):405-408.
17. Ellsworth H, Stellpflug SJ, Cole JB, Dolan JA, Harris CR. A life-threatening flecainide overdose treated with intravenous fat emulsion. Pacing Clin Electrophysiol. 2013;36(3):e87-e89. doi:10.1111/j.1540-8159.2012.03485.x.
Case
An 86-year-old woman, who recently had been seen in the same facility after a ground level fall, presented to the ED with to a 2- to 3-day history of vague abdominal pain, increasing weakness, nausea, and dry heaves.
Upon examination, the patient was unable to stand due to generalized weakness She arrived at the ED via emergency medical services. Her vital signs at presentation were significant for a systolic blood pressure (BP) of 90 mm Hg with a wide complex tachycardia concerning for ventricular tachycardia. The patient’s other vital signers were: heart rate, 136 beats/min; respiratory rate 20 breaths/min; and pulse oximetry was 94% on 4 liters/min of oxygen via nasal cannula.
The patient’s medical history was significant for atrial fibrillation and an indwelling pacemaker, for which she was chronically on flecai
The initial electrocardiogram (ECG) revealed a wide complex rhythm with pacemaker spikes (Figure 1). Based on these findings, electrodes were placed on the patient in the event she required cardioversion. The patient was started on an amiodarone intravenous (IV) drip for presumptive ventricular tachycardia.
During the patient’s evaluation in the ED, she experienced transient drops in BP, which were responsive to an IV fluid bolus of normal saline, and the amiodarone drip was discontinued. The patient’s ECG findings were compared to previous ECG studies, as was her current medication list and prior health issues. After ruling-out other causes, flecainide toxicity was considered high in the differential, and she was given 1 ampule of bicarbonate IV, after which a second ECG showed heart rhythm converted from a wide-complex tachycardia to a paced rhythm, markedly improved from the initial ECG (Figure 2). Similarly, there was a marked improvement in BP.
An interrogation of the patient’s pacemaker revealed an atrial flutter with a rate below detection for mode switch, with one-to-one tracking/pacing. The pacemaker was reprogrammed to divide the DDIR mode with detection rate at 120 mm Hg with mode switch activated. This was felt to be consistent with flecainide toxicity precipitating the cardiac conduction issues.
Laboratory studies showed an elevated flecainide level at 1.39 mcg/mL (upper limits of normal of 1 mcg/mL). Other studies showed worsening congestive heart failure, with a brain natriuretic peptide of 8,057 pg/mL and mild dehydration, with serum creatinine increased from her baseline of 0.9 to 1.38 mg/dL.
The patient’s abdominal pain was further evaluated and she was found to have acute cholecystitis. She was admitted to the intensive care unit with cardiology and general surgery consulting.
Discussion
Flecainide acetate was approved by the Food and Drug Administration in 1984.1It is a Vaughan-Williams class IC antiarrhythmic with a sodium channel blocker action used to treat supra ventricular arrhythmias. The CAST trial in 1989 investigated the efficacy of this class of antiarrhythmics, which resulted in a revision of its role.2 Based on this study, flecainide is not recommended for patients with structural heart disease or coronary artery disease.2,3 However, it is recommended as a first-line therapy for pharmacologic cardioversion and maintenance of normal sinus rhythm in patients with atrial fibrillation and supraventricular tachycardia4,5 without the above caveats.
Class IC agents produce a selective block at the sodium (Na+) channels, resulting in the slowing of cardiac conduction.6,7 This high affinity for Na+ channels combined with slow unbinding kinetics during diastole explain the slowing of recovery time and prolongation of the refractory period.6,8,9 These electrophysiologic properties all can increase the PR, QRS, and QT interval duration. The QT interval is not significantly affected, as most of the QT prolongation is due to the QRS widening.6,10,11 Widening of the QRS by greater than 25% as compared to the baseline value is used as the threshold to decrease dosing or discontinue the use of flecainide.3The toxic effects of flecainide on cardiac conduction can produce prolonged QRS duration of up to 50%, and PR interval up to 30%, especially in rapid heart rates. Signs of intoxication are difficult to discern owing to its nonspecific presentation. A well-documented, but under-recognized, presentation of flecainide toxicity is the transformation of atrial fibrillation to atrial flutter.5,7,9,11-13 The reported rate of this pro arrhythmic effect can be as high as 3.5% to 5%.14,15Flecainide toxicity can occur secondary to chronic ingestion and may be precipitated in mild renal failure. The majority of flecainide is renally excreted and the half-life is 20 hours. Maximum therapeutic effect is seen between levels of 0.2 to 1 mcg/mL with levels greater than 0.7 to 1 mcg/mL associated with adverse effects.9 Systemic effects include dizziness and visual disturbances. A high degree of suspicion for flecainide toxicity is required when the patient’s initial presentation is nonspecific. In this circumstance, real-time bedside interrogation of the pacemaker is invaluable. Early diagnosis and treatment minimizes the risk for adverse sequelae, including death. Treatment includes increasing the excretion of flecainide, symptomatic support (including pacemaker placement, intravenous fat emulsion, or extracorporeal circulatory support) and administration of sodium bicarbonate, to transiently reverse the effect of the sodium channel blockade, in severe cases.15-17
Case
An 86-year-old woman, who recently had been seen in the same facility after a ground level fall, presented to the ED with to a 2- to 3-day history of vague abdominal pain, increasing weakness, nausea, and dry heaves.
Upon examination, the patient was unable to stand due to generalized weakness She arrived at the ED via emergency medical services. Her vital signs at presentation were significant for a systolic blood pressure (BP) of 90 mm Hg with a wide complex tachycardia concerning for ventricular tachycardia. The patient’s other vital signers were: heart rate, 136 beats/min; respiratory rate 20 breaths/min; and pulse oximetry was 94% on 4 liters/min of oxygen via nasal cannula.
The patient’s medical history was significant for atrial fibrillation and an indwelling pacemaker, for which she was chronically on flecai
The initial electrocardiogram (ECG) revealed a wide complex rhythm with pacemaker spikes (Figure 1). Based on these findings, electrodes were placed on the patient in the event she required cardioversion. The patient was started on an amiodarone intravenous (IV) drip for presumptive ventricular tachycardia.
During the patient’s evaluation in the ED, she experienced transient drops in BP, which were responsive to an IV fluid bolus of normal saline, and the amiodarone drip was discontinued. The patient’s ECG findings were compared to previous ECG studies, as was her current medication list and prior health issues. After ruling-out other causes, flecainide toxicity was considered high in the differential, and she was given 1 ampule of bicarbonate IV, after which a second ECG showed heart rhythm converted from a wide-complex tachycardia to a paced rhythm, markedly improved from the initial ECG (Figure 2). Similarly, there was a marked improvement in BP.
An interrogation of the patient’s pacemaker revealed an atrial flutter with a rate below detection for mode switch, with one-to-one tracking/pacing. The pacemaker was reprogrammed to divide the DDIR mode with detection rate at 120 mm Hg with mode switch activated. This was felt to be consistent with flecainide toxicity precipitating the cardiac conduction issues.
Laboratory studies showed an elevated flecainide level at 1.39 mcg/mL (upper limits of normal of 1 mcg/mL). Other studies showed worsening congestive heart failure, with a brain natriuretic peptide of 8,057 pg/mL and mild dehydration, with serum creatinine increased from her baseline of 0.9 to 1.38 mg/dL.
The patient’s abdominal pain was further evaluated and she was found to have acute cholecystitis. She was admitted to the intensive care unit with cardiology and general surgery consulting.
Discussion
Flecainide acetate was approved by the Food and Drug Administration in 1984.1It is a Vaughan-Williams class IC antiarrhythmic with a sodium channel blocker action used to treat supra ventricular arrhythmias. The CAST trial in 1989 investigated the efficacy of this class of antiarrhythmics, which resulted in a revision of its role.2 Based on this study, flecainide is not recommended for patients with structural heart disease or coronary artery disease.2,3 However, it is recommended as a first-line therapy for pharmacologic cardioversion and maintenance of normal sinus rhythm in patients with atrial fibrillation and supraventricular tachycardia4,5 without the above caveats.
Class IC agents produce a selective block at the sodium (Na+) channels, resulting in the slowing of cardiac conduction.6,7 This high affinity for Na+ channels combined with slow unbinding kinetics during diastole explain the slowing of recovery time and prolongation of the refractory period.6,8,9 These electrophysiologic properties all can increase the PR, QRS, and QT interval duration. The QT interval is not significantly affected, as most of the QT prolongation is due to the QRS widening.6,10,11 Widening of the QRS by greater than 25% as compared to the baseline value is used as the threshold to decrease dosing or discontinue the use of flecainide.3The toxic effects of flecainide on cardiac conduction can produce prolonged QRS duration of up to 50%, and PR interval up to 30%, especially in rapid heart rates. Signs of intoxication are difficult to discern owing to its nonspecific presentation. A well-documented, but under-recognized, presentation of flecainide toxicity is the transformation of atrial fibrillation to atrial flutter.5,7,9,11-13 The reported rate of this pro arrhythmic effect can be as high as 3.5% to 5%.14,15Flecainide toxicity can occur secondary to chronic ingestion and may be precipitated in mild renal failure. The majority of flecainide is renally excreted and the half-life is 20 hours. Maximum therapeutic effect is seen between levels of 0.2 to 1 mcg/mL with levels greater than 0.7 to 1 mcg/mL associated with adverse effects.9 Systemic effects include dizziness and visual disturbances. A high degree of suspicion for flecainide toxicity is required when the patient’s initial presentation is nonspecific. In this circumstance, real-time bedside interrogation of the pacemaker is invaluable. Early diagnosis and treatment minimizes the risk for adverse sequelae, including death. Treatment includes increasing the excretion of flecainide, symptomatic support (including pacemaker placement, intravenous fat emulsion, or extracorporeal circulatory support) and administration of sodium bicarbonate, to transiently reverse the effect of the sodium channel blockade, in severe cases.15-17
1. Hudak JM, Banitt EH, Schmid JR. Discovery and development of flecainide. Am J Cardiol. 1984;53(5):17B-20B.
2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med. 1989;321(6):406-412. doi:10.1056/NEJM198908103210629.
3. Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol. 2015;7(2):76-85. doi:10.4330/wjc.v7.i2.76.
4. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747. doi:10.1093/eurheartj/ehs253.
5. Courand PY, Sibellas F, Ranc S, Mullier A, Kirkorian G, Bonnefoy E. Arrhythmogenic effect of flecainide toxicity. Cardiol J. 2013;20:203-205. doi:10.5603/CJ.2013.0035.
6. Holmes B, Heel RC. Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29(1):1-33.
7. Taylor R, Gandhi MM, Lloyd G. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. Br Med J. 2010;340:b4684.
8. Roden DM, Woosley RL. Drug therapy. Flecainide. N Engl J Med. 1986;315(1):36-41.
9. Levis JT. ECG diagnosis: flecainide toxicity. Perm J. 2012;16(4):53.
10. Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RA, Camm AJ. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J. 1982;48(2):140-148.
11. Rognoni A, Bertolazzi M, Peron M, et al. Electrocardiographic changes in a rare case of flecainide poisoning: a case report. Cases J. 2009;2:9137. doi:10.1186/1757-1626-2-9137.
12. Nabar A, Rodriguez LM, Timmermans C, Smeets JL, Wellens HJ. Radiofrequency ablation of “class IC atrial flutter” in patients with resistant atrial fibrillation. Am J Cardiol. 1999;83(5):785-787, A10.
13. Kola S, Mahata I, Kocheril AG. A case of flecainide toxicity. EP Lab Digest. 2015;15(5).
14. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992;117(2):141-150.
15. Lloyd T, Zimmerman J, Griffin GD. Irreversible third-degree heart block and pacemaker implant in a case of flecainide toxicity. Am J Emerg Med. 2013;31(9):1418.e1-e2. doi:10.1016/j.ajem.2013.04.025.
16. Corkeron MA, van Heerden PV, Newman SM, Dusci L. Extracorporeal circulatory support in near-fatal flecainide overdose. Anaesth Intensive Care. 1999;27(4):405-408.
17. Ellsworth H, Stellpflug SJ, Cole JB, Dolan JA, Harris CR. A life-threatening flecainide overdose treated with intravenous fat emulsion. Pacing Clin Electrophysiol. 2013;36(3):e87-e89. doi:10.1111/j.1540-8159.2012.03485.x.
1. Hudak JM, Banitt EH, Schmid JR. Discovery and development of flecainide. Am J Cardiol. 1984;53(5):17B-20B.
2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST). N Engl J Med. 1989;321(6):406-412. doi:10.1056/NEJM198908103210629.
3. Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol. 2015;7(2):76-85. doi:10.4330/wjc.v7.i2.76.
4. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747. doi:10.1093/eurheartj/ehs253.
5. Courand PY, Sibellas F, Ranc S, Mullier A, Kirkorian G, Bonnefoy E. Arrhythmogenic effect of flecainide toxicity. Cardiol J. 2013;20:203-205. doi:10.5603/CJ.2013.0035.
6. Holmes B, Heel RC. Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29(1):1-33.
7. Taylor R, Gandhi MM, Lloyd G. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. Br Med J. 2010;340:b4684.
8. Roden DM, Woosley RL. Drug therapy. Flecainide. N Engl J Med. 1986;315(1):36-41.
9. Levis JT. ECG diagnosis: flecainide toxicity. Perm J. 2012;16(4):53.
10. Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RA, Camm AJ. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J. 1982;48(2):140-148.
11. Rognoni A, Bertolazzi M, Peron M, et al. Electrocardiographic changes in a rare case of flecainide poisoning: a case report. Cases J. 2009;2:9137. doi:10.1186/1757-1626-2-9137.
12. Nabar A, Rodriguez LM, Timmermans C, Smeets JL, Wellens HJ. Radiofrequency ablation of “class IC atrial flutter” in patients with resistant atrial fibrillation. Am J Cardiol. 1999;83(5):785-787, A10.
13. Kola S, Mahata I, Kocheril AG. A case of flecainide toxicity. EP Lab Digest. 2015;15(5).
14. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med. 1992;117(2):141-150.
15. Lloyd T, Zimmerman J, Griffin GD. Irreversible third-degree heart block and pacemaker implant in a case of flecainide toxicity. Am J Emerg Med. 2013;31(9):1418.e1-e2. doi:10.1016/j.ajem.2013.04.025.
16. Corkeron MA, van Heerden PV, Newman SM, Dusci L. Extracorporeal circulatory support in near-fatal flecainide overdose. Anaesth Intensive Care. 1999;27(4):405-408.
17. Ellsworth H, Stellpflug SJ, Cole JB, Dolan JA, Harris CR. A life-threatening flecainide overdose treated with intravenous fat emulsion. Pacing Clin Electrophysiol. 2013;36(3):e87-e89. doi:10.1111/j.1540-8159.2012.03485.x.
